Feasibility and Safety of Weekly Sequential Epirubicin-Paclitaxel as Adjuvant Treatment for Operable Breast Cancer Patients Older than 70 Years

This study conducted in patients over 70 years of age demonstrates the feasibility of weekly adjuvant chemotherapy including anthracyclines and taxanes in a sequential schedule. This regimen is safe in terms of hematologic, nonhematologic, and cardiac toxicities, and showed encouraging efficacy, justifying further studies in geriatric patients.